The hepatitis C virus infection as a systemic disease

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Hepatitis C Virus (HCV) poses a significant global health challenge, affecting approximately 3% of the world's population.
• HCV infection is recognized as a systemic disease, impacting not only the liver but also causing a range of extrahepatic manifestations.
• The precise link between HCV and certain extrahepatic disorders requires further investigation, though its association with lymphoproliferative disorders is well-established.

Purpose of the Study:

• To highlight Hepatitis C Virus (HCV) as a systemic disease with diverse extrahepatic manifestations.
• To emphasize the close relationship between HCV and lymphoproliferative disorders, including mixed cryoglobulinemia and lymphomas.
• To underscore the public health and economic burden of HCV and the therapeutic potential of antiviral eradication.

Main Methods:

• Review of existing data on HCV epidemiology and associated diseases.
• Analysis of the viral tropism of HCV for hepatic and lymphatic cells.
• Examination of the spectrum of HCV-related extrahepatic manifestations.

Main Results:

• HCV infection is confirmed as a systemic disease with established links to liver and lymphoproliferative disorders.
• HCV demonstrates a dual tropism, infecting both liver and lymphatic cells, explaining its impact on these systems.
• A wide array of other HCV-associated conditions involve renal, endocrine, dermatological, cardiovascular, rheumatologic, and central nervous system diseases.

Conclusions:

• HCV infection represents a substantial, often hidden, public health issue with significant direct and indirect costs.
• HCV-related lymphoproliferative disorders are the most prominent extrahepatic manifestation, ranging from pre-lymphomatous conditions to frank lymphomas.
• Eradication of HCV through antiviral therapy is crucial for therapeutic and preventive strategies, positioning HCV as a model for pathogenetic studies.